OPALEYE MANAGEMENT INC. other names

{{ Info.Overview }}
Revenue: {{ Info.Revenue | formatUSD }} Headquarters: {{ Info.Headquarters }}
{{ Info.Homepage }}

Adviser Profile

As of Date:

03/26/2024

Adviser Type:

- Large advisory firm

Number of Employees:

4 33.33%

of those in investment advisory functions:

3

Registration:

SEC, Approved, 10/29/2013

AUM:

432,480,569 2.49%

of that, discretionary:

432,480,569 2.49%

GAV:

421,822,670 4.11%

Avg Account Size:

216,240,285 2.49%

SMA’s:

YES

Private Funds:

1

Contact Info

617 xxxxxxx

Client Types:

+

Advisory Activities:

+

Compensation Arrangments:

+

Reported AUM

Discretionary
Non-discretionary
833M 714M 595M 476M 357M 238M 119M
2015 2016 2017 2018 2019 2020 2021 2022 2023

Recent News

Opaleye Management Inc. buys $641k of Harrow Inc. common stock
03/28/2024

investing.com

Opaleye Management Inc. Bolsters Position in Harrow Inc. with Recent Acquisition
11/17/2023

Related Stocks: HROW, OCUL, CRNX, TELA, SLRN,

gurufocus.com

Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ...
11/17/2021

Related Stocks: KROS, CRNX, OPTN, SMLR, FOLD, MRUS, DTIL, AADI, NCNA, EPIX, MCRB, CMLF, LUMO, KZR, CRDF,

gurufocus.com

Opaleye Management Inc. Buys Kiniksa Pharmaceuticals, Larimar Therapeutics Inc, CM Life ...
08/24/2021

Related Stocks: KNSA, KROS, STRO, OPTN, TELA, LPTX, LRMR, CMLF, FMTX, VIRX, PHVS, CDTX, AUTL, GMTX, CKPT, IMVT, CBIO, FGEN,

gurufocus.com

Opaleye Management Inc. Buys BridgeBio Pharma Inc, Autolus Therapeutics PLC, Gemini ...
06/23/2021

Related Stocks: MGNX, AVEO, CBIO, KNSA, OPTN, SRRA, BBIO, AUTL, GMTX, KROS,

gurufocus.com

Opaleye Management Inc. Buys BridgeBio Pharma Inc, Autolus Therapeutics PLC, Gemini ...
05/28/2021

Related Stocks: MGNX, AVEO, CBIO, KNSA, OPTN, SRRA, BBIO, AUTL, GMTX, KROS,

gurufocus.com


Private Funds Structure

Fund Type Count GAV
Hedge Fund 1 $421,822,670

Similar advisers

Adviser Hedge Fund Liquidity Fund Private Equity Fund Real Estate Fund Securitized Asset Fund Venture Capital Fund Other Fund Total Private Fund GAV AUM # funds
STONY POINT CAPITAL LLC 120.1m - - - - - - 120.1m 450.8m 1
SW INVESTMENT MANAGEMENT LLC 438.4m - - - - - - 438.4m 438.4m 1
PRICE CAPITAL MANAGEMENT, INC. 444.7m - - - - - - 444.7m 523.3m 4
SICART ASSOCIATES, LLC 17.4m - - - - - - 17.4m 364.8m 1
RINGS CAPITAL MANAGEMENT LLC 422.5m - - - - - - 422.5m 422.5m 3
THAMES CAPITAL MANAGEMENT, LLC 231.4m - - - - - - 231.4m 231.4m 1
TRI LOCUM PARTNERS LP 104.1m - - - - - - 104.1m 357.5m 1
OLYMPIAD RESEARCH LP - - - - - - - - 656.8m -
HYPERION CAPITAL ADVISORS LP 280.7m - - - - - - 280.7m 502.9m 2
BAYSHORE CAPITAL ADVISORS, LLC 315.4m - - - - - - 315.4m 454.2m 7

Private Funds



Employees




Top Holdings

Stock Ticker Stock Name $ Position % Position $ Change # Change
415858109 HARROW HEALTH INC $42,784,000 11.00% -22.00% 1.00%
88322Q108 TG THERAPEUTICS INC $37,832,200 10.00% 139.00% 17.00%
00445A100 ACELYRIN INC $30,930,189 8.00% -27.00% 0.00%
67576A100 OCULAR THERAPEUTIX INC $27,072,200 7.00% 33.00% -6.00%
76243J105 RHYTHM PHARMACEUTICALS INC $28,041,700 7.00% 87.00% -7.00%
14888U101 CATALYST PHARMACEUTICALS INC $21,436,112 6.00% 52.00% 4.00%
492327101 KEROS THERAPEUTICS INC $14,214,200 4.00% 24.00% -1.00%
45166A102 IDEAYA BIOSCIENCES INC $11,083,170 3.00% 32.00% 0.00%
22663K107 CRINETICS PHARMACEUTICALS INC $10,940,850 3.00% -1.00% -17.00%
29772L108 ETON PHARMACEUTICALS INC $11,080,905 3.00% 9.00% 4.00%

Brochure Summary

Overview

Firm Description and History Opaleye Management Inc. is a Massachusetts corporation formerly named Risk/Reward Capital Management Corporation formed in 1996. Risk/Reward Capital Management Corporation changed the name to Opaleye Management Inc. in 2014. James Silverman is the sole owner. Business Summary Opaleye provides discretionary investment management services to Opaleye, L.P., a Delaware limited partnership (hereafter the “Fund”). Opaleye GP LLC, a Delaware limited liability company, is the general partner (the “General Partner”) to the Fund. Opaleye is related to the Fund’s General Partner by virtue of common ownership and control. Opaleye manages the Fund on a discretionary basis in accordance with the terms and conditions of the Fund's confidential private placement memorandum and its limited partnership agreement (collectively, the “Offering Documents”). We do not tailor the Fund’s management to the particular needs of any investor in the Fund. The Fund generally invests in equity securities of U.S. and foreign small and mid-cap biotechnology and specialty pharmaceutical and device companies, which may include private companies. Typically, these companies are developing therapies and treatments intended for humans. Interests in the Fund are offered in reliance
upon various exemptions available under the securities laws for transactions in securities not involving a public offering. Investors in the Fund should be aware of additional risks, restrictions on withdrawals and redemptions, and other important information associated with an investment in the Fund. This information is outlined in the Fund's Offering Documents. Accordingly, prospective investors should refer to the Offering Documents for information regarding these important additional considerations and risks. In addition, Opaleye also serves as a portfolio manager and provides discretionary investment management services for a separately managed account (the “Managed Account”). The Managed Account is a parallel managed account that pursues a similar investment objective and strategy and invests side-by-side in most of the same positions as the Fund. We managed the Managed Account as outlined in the management account agreement between Opaleye and the Managed Account client. We do not tailor the Managed Account’s management to the particular needs of the Managed Account client. Client Assets Under Management Discretionary assets under our firm’s management were approximately $421,979,116 as of December 31, 2022. We do not currently manage any non-discretionary assets.